ArticleVeterinary medicine and science2026
Computational and Experimental Development of a Novel Multi-Epitope Vaccine Candidate Against Bovine Leukaemia Virus.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBovine leukaemia virus (BLV) is the causative agent of enzootic bovine leukosis, a chronic infectious disease that causes significant economic losses in the dairy and beef industries worldwide. Despite extensive research, there is no licensed vaccine available for effective prevention and control of BLV infection.
objectivesThis study aimed to design and evaluate a novel multi-epitope vaccine candidate against BLV using an integrated computational and experimental approach to enhance immunogenicity, expression efficiency, and molecular stability.
methodsMajor BLV structural proteins (gp51, gp30, and p24) were analyzed for B- and T-cell epitope prediction using immunoinformatics tools. Selected epitopes were assembled into a single chimeric construct with appropriate linkers and an N-terminal β-defensin adjuvant. The vaccine was evaluated for antigenicity, allergenicity, and physicochemical properties. Structural modelling, molecular docking with Toll-like receptors (TLRs), and RNA stability analyses were performed to assess receptor binding affinity and translational efficiency. Codon optimization for Lactococcus lactis expression was conducted using the JCAT server, and in silico cloning was verified in the NICE pNZ8148 vector.
resultsThe designed vaccine showed high antigenicity (VaxiJen score: 0.7261), non-allergenicity, and stability, with an optimal codon adaptation index (0.94) and GC content (48.55%). Molecular docking revealed strong interactions with TLR9 (z-score = -2.5; van der Waals energy = -56.5 ± 3.8 kcal/mol), suggesting effective immune receptor engagement. RNAfold analysis indicated a stable mRNA structure (MFE = -155.20 kcal/mol), supporting efficient expression.
conclusionsThe multi-epitope vaccine candidate demonstrated favourable immunological, structural, and translational properties, indicating its strong potential as a next-generation recombinant vaccine against BLV. Further in vitro and in vivo validation is warranted to confirm its immunogenicity and protective efficacy in cattle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.